Key Highlights

  • Net loss widened to USD 40.1 million, or USD 1.08 per share, from USD 10.0 million, or USD 0.29, mainly because of a USD 31.3 million non-cash derivative charge.
  • Revenue fell 19% to USD 25.3 million, with CDMO sales down 18% to USD 17.8 million and hyaluronic acid Manufacturing sales down 19% to USD 7.5 million.
  • Gross Margin improved to 27.0% from 25.0%, and operating expenses dropped 29% to USD 7.7 million, narrowing the operating loss to USD 0.9 million.
  • A Merger with Webster Equity Partners affiliates, signed September 27, 2026, offers USD 6.28 per share in cash plus a contingent value right, with closing expected at the end of 2026.

A Derivative Charge Drives the Wider Loss

Lifecore Biomedical (NASDAQ:LFCR) filed its third-quarter 10-Q on November 4, 2026. The company is a contract development and manufacturing organization that fills sterile injectables and makes non-animal hyaluronic acid. Net loss was USD 40.1 million, but operating loss was only USD 0.9 million against USD 3.1 million a year earlier. The gap came from a USD 31.3 million increase in the Fair Value of a related-party Debt derivative liability, which the filing links to the merger agreement raising the probability and bringing forward the timing of a change in control. That Liability stood at USD 62.2 million, including an assumed change in control payment of about USD 30.0 million.

Lower Volume and Pricing Pressure Sales

Revenue declined USD 5.8 million. CDMO fell USD 4.0 million as USD 3.7 million of lower volume and USD 2.3 million of lower pricing, from a concession to a customer in exchange for a multi-year commercial agreement extension, outweighed USD 1.7 million of higher development revenue. Hyaluronic acid Revenue fell USD 1.8 million on timing of the largest customer's Supply chain initiatives. Gross Profit eased to USD 6.8 million despite the better margin. Selling, general and administrative expenses fell USD 2.6 million to USD 6.3 million, helped by lower Stock Compensation and accounting fees, and partly offset by current-period spending related to the proposed merger. Interest expense, net rose 24% to USD 7.9 million as Alcon term Loan interest accumulates.

Merger Terms, Closing Conditions and the Balance Sheet

Each common share would convert into USD 6.28 in cash plus one contingent value right paying milestone amounts if and when payable, while Series A preferred holders would receive a defined conversion amount plus a right. Closing needs stockholder approval and regulatory approvals, and the shares would be Delisted from Nasdaq afterward. Cash was USD 23.0 million at September 30, 2026, against USD 17.5 million at December 31, 2025, while stockholders' Deficit was USD 73.4 million. The filing lists risks around covenants, preferred stock redemptions and further financing if the deal fails.

Where Things Stand

The loss reflects the merger, not worse operations. Lifecore Biomedical (NASDAQ:LFCR) reported an operating loss of USD 0.9 million, narrower than last year, but a USD 31.3 million non-cash charge tied to its debt derivative widened the net loss to USD 40.1 million. Sales fell 19% on volume, a price concession and customer timing. The next markers are the stockholder vote, regulatory approvals, the expected end-of-2026 close and the terms of the contingent value rights. The filing does not give a price reaction, guidance or the CVR milestone amounts.